25 of the Best Oncologists Near Me in Ypsilanti, MI

Dr. Vaishampayan is the Director of the Phase I program at the Rogel Cancer Center, University of Michigan, Ann Arbor MI. Dr. Vaishampayan is a Professor of Internal Medicine and her research is primarily in translational drug development and early phase clinical trials in cancer with a focus on genitourinary malignancies. She has initiated, obtained funding for, and conducted and published many investigator initiated trials with embedded biomarkers and established multidisciplinary collaboration. She has served as site PI of the UO-1 Early Therapeutics Research Grant at Wayne State University. She was also the chair of the solid tumor division of oncology at WSU. She has completed formal leadership traning course and is Fellow of the Advisory Board (FAB). She is the appointed chair of the Advanced Renal committee of SWOG and a member of the Renal task force of the NCI. She is a board member of the Michigan Society of Hematology/Oncology (MSHO) and organizes annual board review course. Additionally, she has served as track leader for the ASCO education committee GU non prostate (Renal and bladder cancer) track. Dr. Vaishampayan attended Wayne State University for her residency and fellowship completion and attended medical school at Byramjee Jeejeebhoy in Pune, India and completed a higher secondary certificate in the field of science at Fergusson College in Pune, India.In her free time, Dr. Vaishampayan enjoys reading, dance, music and travel. Travel, reading (mysteries preferred), follows football. Dr. Vaishampayan is highly rated in 36 conditions, according to our data. Her clinical expertise encompasses Renal Cell Carcinoma (RCC), Prostate Cancer, Urothelial Cancer, Nephrectomy, and Orchiectomy. Dr. Vaishampayan is board certified in Medical Oncology.

Dr. Francis Worden received his medical degree from the Indiana University School of Medicine in 1993. Prior to attending medical school, he worked as a registered pharmacist at a large community hospital in Indianapolis. In 1997, Dr. Worden completed a combined residency in internal medicine and pediatrics at the Detroit Medical Center and finished a medical oncology/hematology fellowship at the University of Michigan. In July 2000, Dr. Worden joined the faculty at the University of Michigan Rogel Cancer Center, where he is currently working as a clinical investigator with both the multidisciplinary head and neck oncology team and the multidisciplinary lung cancer team. Dr. Worden's research interests include organ preservation in head and neck cancer and endocrine oncology. He is the Nancy Wigginton Oncology Research Professor of Thyroid Cancer. Avid competitive swimmer ; cyclist and runner. Dr. Worden is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Laryngeal Cancer, Throat Cancer, Thyroid Cancer, and Head and Neck Squamous Cell Carcinoma (HNSCC). Dr. Worden is board certified in Medical Oncology.

Scott Schuetze is an Oncologist and an Internal Medicine provider practicing medicine in Ann Arbor, Michigan. Dr. Schuetze is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Liposarcoma, Adult Soft Tissue Sarcoma, Angiosarcoma, and Myxoid Liposarcoma.

Dr. Uppal is a board-certified Gynecologic Oncologist and Division Chief for the Gynecology Oncology service at the University of Michigan. He is also the Director of Gynecologic Oncology Initiatives at the Michigan Oncology Quality Consortium (MOQC) - a statewide quality improvement network. Dr. Uppal received his medical degree from the All India Institute of Medical Sciences (AIIMS) in New Delhi, India. He completed his Obstetrics and Gynecology residency at Temple University Hospital in Philadelphia and a fellowship in Gynecology Oncology at the University of Wisconsin in Madison, Wisconsin. He joined the faculty of the University of Michigan in 2014. Dr. Uppal also holds a Master in Business Administration (MBA) from the University of the Michigan Stephen M. Ross School of Business.Dr. Uppal has been in clinical practice for over ten years and is involved in many Quality Improvement Projects in the Division of Gynecologic Oncology, nationally and across Michigan. Widely acknowledged as a thought leader in Gynecology Oncology and quality-of-care, he has authored over 75 peer-reviewed manuscripts and instituted changes in the health system to improve outcomes after surgery, reduce the cost of care and implemented patient-centered care delivery systems. Dr. Uppal is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Hysterectomy, and Oophorectomy. Dr. Uppal is board certified in Gynecologic Oncology and Obstetrics & Gynecology.

The T-cell lymphomas are a heterogeneous and poorly understood group of non-Hodgkin’s lymphomas. The most common T-cell lymphoma in the United States includes a heterogeneous mix of lymphomas that lack distinguishing characteristics and, until recently, remained clinically and molecularly “unspecified”. Improved understanding of T-cell lymphoma pathogenesis and the development of novel therapeutic strategies will be needed to address this challenge and improve outcomes for patients afflicted with these aggressive lymphomas. My group made the landmark discovery that the most common T-cell lymphoma in North America is comprised of two molecularly and clinically distinct subsets. This finding has significant implications for the classification and treatment of these lymphomas. We have also demonstrated that malignant T cells remain dependent upon antigen-presenting cells within the tumor microenvironment and are developing novel therapeutic strategies targeting these cells. Many fundamental questions, including the “cell of origin”, the role of antigen-, costimulatory-, and cytokine-receptor signaling, and the contribution of myeloid-derived antigen-presenting cells in disease pathogenesis remain obscure. My laboratory uses complementary mouse models and primary T-cell lymphoma specimens (in ex vivo and patient-derived xenograft studies) to address these fundamental and clinically relevant questions. We are poised to clinically translate our laboratory-based findings into novel therapeutic strategies that we hope will improve outcomes for patients afflicted with these aggressive lymphomas. I enjoy working with a multidisciplinary team of enthusiastic collaborators who share this common goal. Dr. Wilcox is highly rated in 23 conditions, according to our data. His clinical expertise encompasses T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Peripheral T-Cell Lymphoma, Non-Hodgkin Lymphoma, and Bone Marrow Aspiration. Dr. Wilcox is board certified in Internal Medicine, Hematology, and Medical Oncology.

Dr. Zalupski is an Professor of Medicine in the division of Medical Oncology at the UMMC. He completed medical school, an internal medicine residency and a medical oncology fellowship at Wayne State University in Detroit. Dr. Zalupski's clinical and research interest is in experimental therapeutics of gastrointestinal malignancies and sarcomas. He also serves as the medical director of the Multidisciplinary Pancreatic Cancer Clinic. Dr. Zalupski is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Neuroendocrine Tumor, Familial Pancreatic Cancer, and Pancreaticoduodenectomy. Dr. Zalupski is board certified in Internal Medicine and Medical Oncology.

Dr. Kalemkerian completed his medical education and training at Northwestern University and Johns Hopkins Oncology Center. From 1993-1999, he was a physician-scientist at Wayne State University/Karmanos Cancer Institute in Detroit. Since 1999, he has been on faculty in the Division of Hematology/Oncology at the University of Michigan, where he currently serves as the Associate Division Chief for Faculty Development and Education and the Associate Director of the Hem/Onc Fellowship Program. In addition to his work at UM, Dr. Kalemkerian has served on and led numerous grant review sections, editorial boards, and committees of national and international professional societies. He is a former chair of the NCCN Small Cell Lung Cancer Guideline Panel and the ASCO Scientific Program Committee’s Metastatic NSCLC and Professional Development and Education Tracks. Dr. Kalemkerian’s clinical interest is the care of people with lung cancer, thymic tumors, and mesothelioma, and his academic research interest is clinical and translational trials for thoracic cancers. His honors include the receipt of the American Society of Clinical Oncology’s (ASCO) Excellence in Teaching Award, the University of Michigan Outstanding Clinician Award, and Fellow of ASCO recognition. He has given over 230 invited lectures, authored more than 200 research articles, reviews, commentaries and book chapters, and edited two books on lung cancer. Dr. Kalemkerian is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Lung Adenocarcinoma. Dr. Kalemkerian is board certified in Internal Medicine and Medical Oncology.

Paul Swiecicki is an Oncologist and an Internal Medicine provider practicing medicine in Ann Arbor, Michigan. Dr. Swiecicki is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Throat Cancer, Laryngeal Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), and Oral Squamous Cell Carcinoma. Dr. Swiecicki is board certified in Medical Oncology.

Dr. David Smith is a Professor of Internal Medicine and Urology at the University of Michigan and currently serves as the Associate Chief Clinical Officer for Cancer at Michigan Medicine and the Chief Medical Officer of the Rogel Cancer Center. Throughout his career he has focused on caring for patients with urologic cancers, cancer clinical trials, and the delivery of cancer care. Dr. Smith is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Testicular Cancer, Familial Prostate Cancer, Orchiectomy, and Prostatectomy.

Ajjai Alva is an Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Alva is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Urothelial Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, Nephrectomy, and Lymphadenectomy.

Dr. Talpaz comes to U-M from the University of Texas M.D. Anderson Cancer Center in Houston, where he was a professor of medicine. His research interests include the study of leukemia and immunotherapy, which uses the immune system to fight cancer. He also treats patients with leukemia. Talpaz will continue his research, expanding the U-M Rogel Cancer Center's efforts in hematologic cancer. He will serve as professor of internal medicine at the U-M Medical School. Dr. Talpaz is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Myelofibrosis, Chronic Myelogenous Leukemia (CML), Myeloproliferative Neoplasms (MPN), and Polycythemia Vera. Dr. Talpaz is board certified in Internal Medicine and Medical Oncology.

Dr. Sofia Merajver received a doctoral degree in physics from the University of Maryland and a medical degree from the University of Michigan. She completed a residency in internal medicine and a fellowship in oncology at the University of Michigan before joining the faculty in 1994. Dr. Merajver, an expert in breast cancer genetics, is the medical director of the Breast and Ovarian Cancer Risk Evaluation Program at the U-M Rogel Cancer Center. Her research interests include the molecular genetics of breast cancer, gene function and cancer risk assessment. She enjoys literature, music and outdoor activities with her family. Dr. Merajver is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Inflammatory Breast Cancer, Breast Cancer, Triple-Negative Breast Cancer, and Angiosarcoma. Dr. Merajver is board certified in Medical Oncology.

Zachery Reichert is an Oncologist and an Internal Medicine provider practicing medicine in Ann Arbor, Michigan. Dr. Reichert is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Urothelial Cancer, Bladder Cancer, and Prostatectomy.

Christopher Lao is an Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Lao is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Melanoma, Merkel Cell Carcinoma, Melanoma of the Eye, and Metastatic Uveal Melanoma.

Dr. Morikawa joined the faculty in August 2014. After earning her M.Mus. in Piano Performance and M.PH in Epidemiology and Biostatistics from Boston University, Dr. Morikawa received her MD/Ph.D. at the Emory University School of Medicine. After completing her internal medicine residency training at Emory, she underwent fellowship training in Medical Oncology at Memorial Sloan Kettering Cancer Center. In 2014, she joined the faculty of the University of Michigan. She specializes in the care of patients with breast cancer at the Rogel Cancer Center. Her research involves clinical and translational investigations in breast cancer as well as brain and leptomeningeal metastases from solid tumors. Dr. Morikawa is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, HER-2 Positive Breast Cancer, Inflammatory Breast Cancer, and Angiosarcoma. Dr. Morikawa is board certified in Internal Medicine and Medical Oncology.

Dr. Schott is a Professor of Medicine and is the Associate Director of Clinical Research for the Rogel Cancer Center. She is an expert in the field of breast cancer, has an active breast cancer practice, and frequently gives lectures and publishes about breast cancer treatment. Her research is focused on the development of new treatments for breast cancer, and the testing of these treatments in clinical trials. Dr. Schott is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Inflammatory Breast Cancer, Angiosarcoma, HER2 Negative Breast Cancer, and Tissue Biopsy.

Nithya Ramnath is a Hematologist and an Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Ramnath is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Pleuropulmonary Blastoma.

Leslie Fecher, MD, joined the faculty on from Indiana University School of Medicine's Simon Cancer Center. Dr. Fecher completed her BA in Biochemistry at Rice University in Houston, and earned her MD from Indiana University School of Medicine. She completed her residency at University of Texas Southwestern in Dallas, followed by an Oncology Fellowship at Johns Hopkins' Sidney Kimmel Comprehensive Cancer Center in Baltimore. Dr. Fecher was an assistant professor of medicine at the Abramson Cancer Center in Philadelphia for four years where she held a secondary appointment in Dermatology. She subsequently joined the faculty at Indiana University in 2011. Dr. Fecher is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Melanoma, Merkel Cell Carcinoma, Melanoma of the Eye, Metastatic Uveal Melanoma, and Tissue Biopsy.

Dr. Norah Lynn Henry is a medical oncologist, Associate Director of Community Outreach and Engagement at the Rogel Cancer Center, and Co-Chair of the Symptom Management and Survivorship Committee for the SWOG Cancer Research Network.Dr. Henry specializes in the care of patients with all stages and all types of breast cancer. Her research focuses on personalizing treatment for breast cancer. She studies treatments for breast cancer as well as ways to manage symptoms and side effects that arise from the cancer or its treatment. Her goal is to provide effective treatments for breast cancer while maintaining the quality of life of each patient. In addition, she works with scientists at the University of Michigan to translate their lab findings into clinical trials. Dr. Henry is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Salpingo-Oophorectomy. Dr. Henry is board certified in Medical Oncology.

Max Wicha is an Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Wicha is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, and Tissue Biopsy.

Rajen Mody is a Hematologist and an Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Mody is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Infantile Neutropenia, Glioma, and Bone Marrow Aspiration.

Mark Kaminski is an Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Kaminski is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Gastric Lymphoma, and Bone Marrow Aspiration.

Janice Liu is an Oncologist practicing medicine in Ypsilanti, Michigan. Dr. Liu is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Endometrial Cancer, Malignant Mixed Mullerian Tumor, Endometrial Stromal Sarcoma, and Vaginal Cancer.

Philip Stella is an Oncologist practicing medicine in Ypsilanti, Michigan. Dr. Stella is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Colorectal Cancer, Pancreatic Cancer, and Pleuropulmonary Blastoma.

Dr. Sahai is the Leader of the Gastrointestinal Medical Oncology Section and Associate Professor in the Division of Hematology-Oncology, Department of Internal Medicine. Dr. Sahai is also a member of the University of Michigan Rogel Cancer Center and Director of Tumor Response Assessment Core.Dr. Sahai attended medical school at the Government Medical College at Amritsar with the Baba Farid University of Health Science in India. He then completed his Masters in Clinical Epidemiology at Harvard School of Public Health followed by Internal Medicine residency training at University of Pittsburgh where he met his wife. He completed his fellowship in Hematology-Oncology at Northwestern University where he also served as the Chief Fellow. Subsequently, Dr. Sahai joined University of Michigan as Assistant Professor in Internal Medicine in 2013.Dr. Sahai is a clinician-scientist who sees patients within the Multidisciplinary Pancreatic and Liver Tumor programs. As a clinical investigator he is the Principal Investigator on several investigator-initiated clinical trials open across the U.S. His translational research program leverages the pancreaticobiliary cancer biobanks that he directs for the therapeutic investigation of novel compounds in patient-derived cell lines and xenograft models to help develop novel phase 1/2 investigator-initiated clinical trials. Dr. Sahai is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Cancer, Familial Pancreatic Cancer, and Neuroendocrine Tumor.